NCT05601180View on ClinicalTrials.gov

Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.

NACompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

October 27, 2022

Primary Completion Date

January 15, 2024

Study Completion Date

January 15, 2024

Conditions
AsthmaChronic Obstructive Pulmonary DiseaseLong COVID
Interventions
OTHER

Respicure®

Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.

OTHER

Standard of care

standard treatment is prescribed by the treating physician.

Trial Locations (8)

Unknown

CHU Beni Messous/Pneumologie A, Algiers

CHU Beni Messous/Pneumologie B, Algiers

CHU Annaba/Pneumo-phtisiologie, Annaba

EPH Batna/Pneumo-phtisiologie, Batna City

CHU Constantine/Pneumo-phtisiologie, Constantine

EPH Laghouat/Pneumo-phtisiologie, Laghouat

CHU Oran/Pneumo-phtisiologie B, Oran

CHU Sidi Bel Abbes/Pneumo-phtisiologie, Sidi Bel Abbes

Sponsors

Lead Sponsor

Beker Laboratories
All Listed Sponsors
lead

Beker Laboratories

INDUSTRY

NCT05601180 - Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID. | Biotech Hunter | Biotech Hunter